Conversion to Wet AMD after Izervayvu 84 fois83 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatment15 Mars 2026
Conversion to Wet AMD after Izervayvu 76 fois83 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatment15 Mars 2026
Conversion to Wet AMD after Izervayvu 68 fois83 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatment15 Mars 2026
Conversion to Wet AMD after Izervayvu 106 fois83 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatment15 Mars 2026
Conversion to Wet AMD after Izervayvu 100 fois83 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatment15 Mars 2026
Conversion to Wet AMD after Izervayvu 79 fois83 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatment15 Mars 2026
Conversion to Wet AMD after Izervayvu 91 fois83 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatment15 Mars 2026
Conversion to Wet AMD after Izervayvu 82 fois83 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatment15 Mars 2026
Conversion to Wet AMD after Izervayvu 108 fois83 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatment15 Mars 2026
Conversion to Wet AMD after Izervayvu 71 fois83 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatment15 Mars 2026
Conversion to Wet AMD after Izervayvu 72 fois83 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatment15 Mars 2026
Conversion to Wet AMD after Izervayvu 63 fois83 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatment15 Mars 2026
Conversion to Wet AMD after Izervayvu 82 fois83 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatment15 Mars 2026
Conversion to Wet AMD after Izervayvu 87 fois83 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatment15 Mars 2026
Conversion to Wet AMD after Izervayvu 71 fois83 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatment15 Mars 2026
Conversion to Wet AMD after Izervayvu 83 fois83 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatment15 Mars 2026
Conversion to Wet AMD after Izervayvu 69 fois83 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatment15 Mars 2026
Peripapillary CNVM No Treatmentvu 107 fois85 year old with peripapillary CNVM watched for many years.18 Février 2026
Peripapillary CNVM No Treatmentvu 58 fois85 year old with peripapillary CNVM watched for many years.18 Février 2026
Peripapillary CNVM No Treatmentvu 64 fois85 year old with peripapillary CNVM watched for many years.18 Février 2026
Peripapillary CNVM No Treatmentvu 71 fois85 year old with peripapillary CNVM watched for many years.18 Février 2026
Peripapillary CNVM No Treatmentvu 66 fois85 year old with peripapillary CNVM watched for many years.18 Février 2026
Peripapillary CNVM No Treatmentvu 61 fois85 year old with peripapillary CNVM watched for many years.18 Février 2026
Peripapillary CNVM No Treatmentvu 66 fois85 year old with peripapillary CNVM watched for many years.18 Février 2026
Peripapillary CNVM No Treatmentvu 67 fois85 year old with peripapillary CNVM watched for many years.18 Février 2026
Peripapillary CNVM No Treatmentvu 79 fois85 year old with peripapillary CNVM watched for many years.18 Février 2026
Peripapillary CNVM No Treatmentvu 57 fois85 year old with peripapillary CNVM watched for many years.18 Février 2026
Peripapillary CNVM No Treatmentvu 63 fois85 year old with peripapillary CNVM watched for many years.18 Février 2026
Peripapillary CNVM No Treatmentvu 94 fois85 year old with peripapillary CNVM watched for many years.18 Février 2026
Peripapillary CNVM No Treatmentvu 65 fois85 year old with peripapillary CNVM watched for many years.18 Février 2026
Peripapillary CNVM No Treatmentvu 92 fois85 year old with peripapillary CNVM watched for many years.18 Février 2026
Peripapillary CNVM No Treatmentvu 89 fois85 year old with peripapillary CNVM watched for many years.18 Février 2026
Peripapillary CNVM No Treatmentvu 73 fois85 year old with peripapillary CNVM watched for many years.18 Février 2026
Peripapillary CNVM No Treatmentvu 102 fois85 year old with peripapillary CNVM watched for many years.18 Février 2026
Peripapillary CNVM No Treatmentvu 80 fois85 year old with peripapillary CNVM watched for many years.18 Février 2026
Peripapillary CNVM No Treatmentvu 88 fois85 year old with peripapillary CNVM watched for many years.18 Février 2026
Peripapillary CNVM No Treatmentvu 84 fois85 year old with peripapillary CNVM watched for many years.18 Février 2026
Peripapillary CNVM No Treatmentvu 80 fois85 year old with peripapillary CNVM watched for many years.18 Février 2026
Peripapillary CNVM No Treatmentvu 76 fois85 year old with peripapillary CNVM watched for many years.18 Février 2026
Peripapillary CNVM No Treatmentvu 77 fois85 year old with peripapillary CNVM watched for many years.18 Février 2026
Peripapillary CNVM No Treatmentvu 79 fois85 year old with peripapillary CNVM watched for many years.18 Février 2026
Peripapillary CNVM No Treatmentvu 98 fois85 year old with peripapillary CNVM watched for many years.18 Février 2026
Peripapillary CNVM No Treatmentvu 57 fois85 year old with peripapillary CNVM watched for many years.18 Février 2026
Peripapillary CNVM No Treatmentvu 83 fois85 year old with peripapillary CNVM watched for many years.18 Février 2026
Peripapillary CNVM No Treatmentvu 81 fois85 year old with peripapillary CNVM watched for many years.18 Février 2026
Peripapillary CNVM No Treatmentvu 84 fois85 year old with peripapillary CNVM watched for many years.18 Février 2026
Post Anti-VEGF RPE Tear (Vabysmo)vu 85 fois87 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/40011 Janvier 2026
Post Anti-VEGF RPE Tear (Vabysmo)vu 91 fois87 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/40011 Janvier 2026
Post Anti-VEGF RPE Tear (Vabysmo)vu 100 fois87 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/40011 Janvier 2026
Post Anti-VEGF RPE Tear (Vabysmo)vu 110 fois87 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/40011 Janvier 2026
Post Anti-VEGF RPE Tear (Vabysmo)vu 112 fois87 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/40011 Janvier 2026
Post Anti-VEGF RPE Tear (Vabysmo)vu 107 fois87 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/40011 Janvier 2026
Post Anti-VEGF RPE Tear (Vabysmo)vu 111 fois87 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/40011 Janvier 2026
Post Anti-VEGF RPE Tear (Vabysmo)vu 93 fois87 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/40011 Janvier 2026
Post Anti-VEGF RPE Tear (Vabysmo)vu 92 fois87 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/40011 Janvier 2026
Post Anti-VEGF RPE Tear (Vabysmo)vu 88 fois87 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/40011 Janvier 2026
Post Anti-VEGF RPE Tear (Vabysmo)vu 115 fois87 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/40011 Janvier 2026
Post Anti-VEGF RPE Tear (Vabysmo)vu 95 fois87 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/40011 Janvier 2026
Post Anti-VEGF RPE Tear (Vabysmo)vu 104 fois87 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/40011 Janvier 2026
Post Anti-VEGF RPE Tear (Vabysmo)vu 83 fois87 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/40011 Janvier 2026
Post Anti-VEGF RPE Tear (Vabysmo)vu 114 fois87 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/40011 Janvier 2026
Post Anti-VEGF RPE Tear (Vabysmo)vu 108 fois87 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/40011 Janvier 2026
Post Anti-VEGF RPE Tear (Vabysmo)vu 83 fois87 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/40011 Janvier 2026
Post Anti-VEGF RPE Tear (Vabysmo)vu 102 fois87 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/40011 Janvier 2026
Idiopathic Polypoidal Choroidal Vasculopathyvu 199 fois83 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDT12 Février 2025
Idiopathic Polypoidal Choroidal Vasculopathyvu 179 fois83 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDT12 Février 2025
Idiopathic Polypoidal Choroidal Vasculopathyvu 160 fois83 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDT12 Février 2025
Idiopathic Polypoidal Choroidal Vasculopathyvu 189 fois83 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDT12 Février 2025
Idiopathic Polypoidal Choroidal Vasculopathyvu 171 fois83 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDT12 Février 2025
Idiopathic Polypoidal Choroidal Vasculopathyvu 190 fois83 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDT12 Février 2025
Idiopathic Polypoidal Choroidal Vasculopathyvu 191 fois83 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDT12 Février 2025
Idiopathic Polypoidal Choroidal Vasculopathyvu 172 fois83 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDT12 Février 2025
Idiopathic Polypoidal Choroidal Vasculopathyvu 151 fois83 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDT12 Février 2025
Idiopathic Polypoidal Choroidal Vasculopathyvu 192 fois83 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDT12 Février 2025
Idiopathic Polypoidal Choroidal Vasculopathyvu 178 fois83 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDT12 Février 2025
Idiopathic Polypoidal Choroidal Vasculopathyvu 173 fois83 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDT12 Février 2025
Idiopathic Polypoidal Choroidal Vasculopathyvu 140 fois83 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDT12 Février 2025
Idiopathic Polypoidal Choroidal Vasculopathyvu 151 fois83 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDT12 Février 2025
Idiopathic Polypoidal Choroidal Vasculopathyvu 129 fois83 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDT12 Février 2025
Idiopathic Polypoidal Choroidal Vasculopathyvu 149 fois83 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDT12 Février 2025
Idiopathic Polypoidal Choroidal Vasculopathyvu 144 fois83 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDT12 Février 2025
Idiopathic Polypoidal Choroidal Vasculopathyvu 113 fois83 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDT12 Février 2025
Idiopathic Polypoidal Choroidal Vasculopathyvu 156 fois83 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDT12 Février 2025
Wet AMD - Occult CNVM and Geographic atrophyvu 140 fois77 year old female with mild vision loss - 20/32 - responded to Avastin19 Décembre 2024
Wet AMD - Occult CNVM and Geographic atrophyvu 174 fois77 year old female with mild vision loss - 20/32 - responded to Avastin19 Décembre 2024
Wet AMD - Occult CNVM and Geographic atrophyvu 133 fois77 year old female with mild vision loss - 20/32 - responded to Avastin19 Décembre 2024
Wet AMD - Occult CNVM and Geographic atrophyvu 144 fois77 year old female with mild vision loss - 20/32 - responded to Avastin19 Décembre 2024
Wet AMD - Occult CNVM and Geographic atrophyvu 146 fois77 year old female with mild vision loss - 20/32 - responded to Avastin19 Décembre 2024
Wet AMD - Occult CNVM and Geographic atrophyvu 128 fois77 year old female with mild vision loss - 20/32 - responded to Avastin19 Décembre 2024
Wet AMD - Occult CNVM and Geographic atrophyvu 128 fois77 year old female with mild vision loss - 20/32 - responded to Avastin19 Décembre 2024
Wet AMD - Occult CNVM and Geographic atrophyvu 134 fois77 year old female with mild vision loss - 20/32 - responded to Avastin19 Décembre 2024
Wet AMD - Occult CNVM and Geographic atrophyvu 129 fois77 year old female with mild vision loss - 20/32 - responded to Avastin19 Décembre 2024
Wet AMD - Occult CNVM and Geographic atrophyvu 188 fois77 year old female with mild vision loss - 20/32 - responded to Avastin19 Décembre 2024
Wet AMD - Occult CNVM and Geographic atrophyvu 188 fois77 year old female with mild vision loss - 20/32 - responded to Avastin19 Décembre 2024
Wet AMD - Occult CNVM and Geographic atrophyvu 152 fois77 year old female with mild vision loss - 20/32 - responded to Avastin19 Décembre 2024
Wet AMD - Occult CNVM and Geographic atrophyvu 133 fois77 year old female with mild vision loss - 20/32 - responded to Avastin19 Décembre 2024
Wet AMD - Occult CNVM and Geographic atrophyvu 153 fois77 year old female with mild vision loss - 20/32 - responded to Avastin19 Décembre 2024
Wet AMD - Occult CNVM and Geographic atrophyvu 178 fois77 year old female with mild vision loss - 20/32 - responded to Avastin19 Décembre 2024
Wet AMD - Occult CNVM and Geographic atrophyvu 116 fois77 year old female with mild vision loss - 20/32 - responded to Avastin19 Décembre 2024
Wet AMD - Occult CNVM and Geographic atrophyvu 158 fois77 year old female with mild vision loss - 20/32 - responded to Avastin19 Décembre 2024
